BCL2L1 and Miyoshi myopathy: Similar to when bortezomib was added as a single agent, BCL-xL was inhibited completely (RPMI 8226) or inhibited 63% (U266B1) in MM cells cultured alone and treated with a triple-drug cocktail (Figure 2C,D).